C. G. Langdon (1), N. Wiedemann (2), M. A. Held (1) (6), R. Mamillapalli (1), P. Iyidogan (1), N. Theodosakis (1), J. T. Platt (1) (3), F. Levy (2), G. Vuagniaux (2), S. Wang (5), M. W. Bosenberg (1) (4) and D. F. Stern (1)
Oncotarget. 2015 Oct 16. doi: 10.18632/oncotarget.6138.
Department of Pathology and Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
Debiopharm International SA, Lausanne, Switzerland
Breast Medical Oncology Group, Yale Cancer Center, New Haven, CT, USA
Departments of Dermatology and Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA
Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA, USA